Despite the large variety of modified nucleosides that have been reported, the preparation of constrained 4'spirocyclic adenosine analogues has received very little attention.W ed iscovered that the [2+ +2]-cycloaddition of dichloroketeneo nr eadily available 4'-exo-methylenef uranose sugars efficientlyr esults in the diastereoselective formation of novel 4'-spirocyclobutanones. The reaction mechanism was investigated via density functional theory (DFT) and found to proceed either via an on-synchronous or stepwise reactions equence, controlled by the stereochemistry at the 3'-position of the sugar substrate. The obtained dichlorocyclobutanones were converted into nucleoside analogues, providing access to an ovel class of chiral 4'-spirocyclobutyl adenosine mimetics in eight steps from commercially available sugars.A ssessment of the biological activity of de-signed4 '-spirocyclic adenosinea nalogues identified potent inhibitors for protein methyltransferase target PRMT5.
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In recent years, mimetics of S-adenosyl-l-methionine (SAM, 1) have found applications in drug discoverya sp rotein methyltransferase( PMT) inhibitors foro ncology targets, [1] as exemplified by PRMT5i nhibitor [2] and the clinical candidate pinometostat (3)f or DOT1L [3] (Figure 1 ). These selected examples indicate that the nucleoside moiety of SAM (1)i sg enerally well conserved, whereas diversem odificationsa tt he 5'-position of the adenosine analogues are tolerated. Consequently, this encourages an exploration of the chemicals pace for the discoveryo fs electiveS AM (1)a nalogues for methyltransferase targets of interest.
An interesting example of ac onstrained SAM (1)a nalogue and potent (35 nm)m ethyltransferase inhibitor for PRMT5i s the natural product dehydrosinefungin (4), [4] for which no total synthesis has been described. The impact of the 4'-exocyclic double bond in 4 as ac onformational constraint is emphasized by the observation that the saturated analogueo f4 (sinefungin) is nearly 250-fold less potent on the same target, and displays ap oor selectivity against ap anel of methyltransferases. [5] In this respect, the incorporation of as pirocyclobutyl ring can be considereda samimetic of the exocyclic alkene in dehydrosinefungin (4) , with the potential to identify novel,b iologically active structurally constrained SAM (1)a nalogues. Indeed,c onformationalr estriction via cyclization is af requently used approach in drug discovery [6] and has provent ob eav aluable strategytowards nucleoside analogues with an enhanced affinity and specificity for the nucleoside binding site in proteins. [7] Remarkably,d espitet he multiple exampleso f5 ' modified nucleosides, the preparation of 4'-spirocyclobutyl adenosine scaffolds of type 5 has not been reported. Focussing on 4'-spirocarbocyclic nucleosides, only few examples describe 4'-spirocyclopentyl [8] and -propyl [9] nucleoside analogues, which are typicallyp reparedv ia lengthys ynthetic routes or display limited opportunity for diversificationo ft he spirocyclic scaffold structures. The development of as trategy that enables an efficient synthesis towards unknown adenosine core scaffold 5 is thus of high interestt oo btain innovativep latform building blocks that can be used in medicinal chemistry for the design of constrained analogues of SAM (1).
In previous reports, Redlich et al. described the synthesis of 4'-spirocyclic furanoses of type 7 using a[ 2 + +2]-cycloaddition of dichloroketeneo nexo-ethylidene furanose substrates 6a and 6b,a ffording dichlorocyclobutanones 7a and 7b,r espectively (Scheme 1). [10] Althought his is an interesting transformation, such cycloaddition on the corresponding ribose derivative 8 would generate far more potential as novel building block for nucleoside analogues, however,s ubjecting exo-ethylidene riboside 8 to identicalc ycloaddition conditions resulted exclusively in the formation of side product 9.T he furtherd erivatization of cyclobutanones 7a and 7b wasn ot investigated, nor have any efforts been described to prepare the correspondingn ucleoside analogues. Despite the failure of the [2+ +2]-cycloaddition with dichloroketene on ribose analogue 8, we set out to evaluatet he potential of 4'-exo-methylene ribosides substrates (type 10,S cheme 1), as this could directly result in unsubstituted dichlorocyclobutanones of type 11.A n attractive asset of this approach is that substrates of type 10 can be readilyp repared from chiralp ools ugars on multigram scale. [11] To obtain 4'-spirocyclic adenosine analogueso ft ype 5,d ifferent types of protected 4'-exo-methylene substrates were prepared. In contrast to the failed cycloaddition reaction on ribose analogue 8,w eu nexpectedly observedt hat when substrate 12 a wasi nitially subjected to standard [2+ +2]-cycloaddition conditions with dichloroketene, [10] aclean and diastereoselective transformation towards dichlorocyclobutanone 13 a was obtained (Scheme 2). Encouraged by this, 4'-exo-methylene substrates 12 b and 12 c weree valuated using identicalc onditions, which also resulted in ad iastereoselective reactiont o afford cycloadducts 13 b and 13 c,r espectively.I na ll cases, the facial selectivityo ft he [2+ +2]-cycloaddition is directed by the 3' substituent, resultingi no ptically pure dichlorocyclobutanones 13 a-13 c.A ccordingly, the synthesis of stable dichlorocyclobutanones 13 a and 13 c was successfully reproduced on multigram scale.
Scheme1.Previouswork and current study. [12] Scheme2.[2+ +2]-Cycloadditions on 4'-exo-methylene furanoses 12 a-12 c To substantiate the observed stereoselectivityi nt he [2+ +2]cycloaddition on substrates 12 a-12 c,t he energy profiles of the approachf rom both the a and b faces were calculated using DFT.T hese results were found to corroborate the experimentalo bservations, that is, the observed approach of dichloroketene from the b facet owards 13 a-13 c was found to proceed via an on-synchronous concertedr eaction mechanism, which corresponds to al ower energy transition state compared to an approach from the a face.I ndeed, calculations for the addition of the ketene at the a face showed that as econd energy barrier( 16 c,F igure 2) needs to be overcomet hrough a two-step mechanism,asd isplayed for cycloadduct 13 c.
Interestingly,w hen comparing our findings to the reported synthesis of 7a and 7b starting from 4'-exo-ethylidene 6a and 6d,t he opposite facial selectivity is observed. Moreover,D FT calculations of the reaction mechanism towards cycloadduct 7b are supportive for the observed addition at the a face of 6b.T os ubstantiate theseo bservations, we verified if the stereoselectivity of the cycloaddition can be controlled via steric interactions at the 3'-position of the furanose ring using 4'-exo-methylene substrates 14 a-14 b.T his hypothesisc ould be verifieda st he structureso fc ycloadducts 15 a-15 b,o btained as single isomers, were elucidated via single-crystal Xray diffraction (sc-XRD) [13] and found to be opposite compared to 13 a-13 c (Scheme 2).T he stereochemistry at the 3'-position of thef uranose ring is thus directingt he approacho fd ichloroketene to eitherthe a or the b face,enabling stereoselective access to both facial isomers by selecting the appropriate substrate.
Having multigram quantities of 4'-spirocyclic furanoses 13 a and 13 c in hand, ar eductived echlorination using zinc and acetic acid afforded ketones 17 a and 17 b,r espectively (Scheme 3). At this stage, the stable reaction products 17 a and 17 b could be efficiently purified via silica gel chromatography and were isolatedi ng ood yields. Consecutively, the reduction of ketone 17 a showed ah igh selectively (94 %) for cis-isomer 18 a when LiAlH 4 was used as reducinga gent. Am ore extensives creening of reduction conditions was performed on ketone 17 b,w here the highest selectivityt owards cis-isomer 19 a was noticed withN aBH 4 in methanola tl ow temperatures. The preference for cis-isomers 18 a and 19 a is believed to be ar esult of unfavourable electrostatic repulsions between the endo-cyclic oxygen of the furanose ring and the hydride, which is in accordance with literature reports on 3-alkoxycyclobutanone reductionst owards cis-3-alkoxycyclobutanols. [14] To increaset he potentialo f4 '-spirocyclobutyl furanoses as platform building blocks towards ar ange of novel constrained nucleoside analogues, access to the corresponding trans isomers 18 b and 19 b wasd esired. AM itsunobu inversionw as successfully applied on alcohols 18 a and 19 a,a ffording the corresponding benzoates 20 a and 21 a,a llowing at the same time an efficient separation of the minor isomer by silica gel chromatography.
With the purpose of transforming spirocyclics caffolds 21 a and 21 b into corresponding adenosine analogues, Vorbrüggen glycosylation was planned to introduce the nucleobase. To this end, furanoses 21 a and 21 b were reactedw ith the in situ silylated 6-chloropurine (22), followedb yt he addition of trimethylsilyl triflate (TMSOTf) and heatingt o8 0 8C( Scheme 4). Using these conditions, we were pleased to observe as tereoselectivea nd high yielding conversion from 21 a and 21 b towards the desired b-N9 nucleosides 23 a and 23 b,r espectively. Final deprotection and amine substitution of the 6-chloropurine moiety in 23 a and 23 b with ammonia proceeded efficiently in one step, affording the desired spirocyclic adenosine analogues 5a and 5b in high yields.
Next, we investigated the ring puckering of 5a and 5b because the substitution of the furanose ring is known to have Scheme3.Reduction of dichlorocyclobutanones 13 a and 13 c to alcohols 18 a and 19 a,respectively,and Mitsunobu inversion.R eduction conditions: LiAlH 4 ,THF, À78 8C (18), NaBH 4 ,M eOH, À78 8C ( 19) .
an important impact on the adopted conformation and hence, affects the biological properties in nucleosides and corresponding oligonucleotides. [15] At first, sc-XRD clearly demonstrated that 4'-spironucleoside 5a adopts a South (2'-endo) conformation in the crystal lattice. Additionally,N MR spectroscopy was used to relate the 1 H-1 Hs calar couplings ( 3 J 1'-2' )t o the relative percentage of North/South ring puckers, [16] which showedapreference for the South conformationf or both cis (5b)a nd trans (5a)n ucleoside analogues of 73 and 69 %, respectively. [17] Furthermore, vibrational circular dichroism (VCD) was employedt os tudy the conformation of 5a and 5b,a s this techniqueo ffers the advantage that the experimental spectrald ata can be validatedv ia comparison with in silico lowest energy conformations. [18] Also in this case, ap reference for a South ring puckering was established for spirocyclic nucleosides analogues 5a and 5b.T hese results are supportive for expanding novel constrained scaffolds 5a and 5b to create ligandsf or protein methyltransferase PRMT5, since severalc ocrystal structures with SAM (1)a nalogues sinefungin and dehydrosinefungin (4)d emonstrate that South ring puckering is a commonf eature, whereas the ring conformation of sinefungin bound to other methyltransferases does not alwaysa dopt a South ring pucker. [19] To demonstrate that novel 4'-spirocyclic adenosine scaffolds (5a-5b)c an be used to design SAM (1)c ompetitive inhibitors of PMTs, we introduced a2 -aminoquinoline heterocycle at the cyclobutanol moiety,a st his has been reported to be as uitable pharmacophore group in the preparation of PRMT5 inhibitors. [20, 21] To achieve this, we performed aM itsunobur eaction on cyclobutanols 18 a and 18 b using hydroxyquinoline 24.A s exemplified in Scheme5 for building block 18 b,t his reaction efficiently afforded the coupled product 25 a with inversiono f stereochemistry at the cyclobutyl ring. Subsequently,aprotecting group switch was performed to convert 25 a towards the corresponding triacetate 26 a in order to obtain as uitable substrate for Vorbrüggen glycosylation. Similart ot he introduction of 6-chloropurine (22)o ns ubstrates 21 a and 21 b (Scheme 4), buildingb lock 26 a was efficiently converted towards the desired b-nucleoside intermediate, and sequential treatment with aqueous ammonia in dioxane at elevatedt emperature afford the envisioned compound 27 a (Scheme 5).
Next, we examined the in vitro activity of novel 4'-spirocyclic nucleoside analogues towards the PRMT5/MEP50 multimer complex. In this assay,w ef irst evaluated the unmodified 5a (trans)a nd 5b (cis), which showede nzymatic activitiesi nt he micromolar range (Table 1) , corresponding to inhibition values that are close to adenosine as ab enchmark ligand. [20] This indicates that the 4'-spirocyclobutyl ring is atolerated modification in the SAM binding pocket of PRMT5. Interestingly,t he introductiono fa2-aminoquinoline pharmacophore at the cyclobutanol group in compounds 27 a and 27 b significantly improvedt he activity compared to spirocyclic adenosine analogues 5a and 5b,r esulting in an early 400-fold increase in potency for compound 27 b (Table 1) . These results clearlyd emonstrate that novel core scaffolds of type 5 are valuable buildingb locks fort he preparation of targetc ompounds for SAM (1)c ompetitive inhibition of PRMT5.
In conclusion, we have developed as calablea nd diastereoselective[ 2 + +2]-cycloaddition reaction using dichloroketene on 4'-exo-methylene furanoses ubstrates, resulting in the formation of optically pure 4'-spirocyclic dichlorocyclobutanones. Calculations by DFT showed that the reaction proceeds via a Scheme4.Vorbrüggen glycosylation and deprotectiont owards 4'-spirocyclic adenosine analogues 5a and 5b.
Scheme5.Mitsunobu reaction on spirocyclobutanol 18 b and Vorbrüggen glycosylation towardscompounds 27 a and 27 b (in analogy, not depicted). 2019, 25,15419 -15423 www.chemeurj.org nonsynchronous concerted or as tepwise mechanism, which is controlled by the stereochemistry at the 3'-position of the sugar substrate. Dichlorocyclobutanone scaffolds have been convertedt owards the corresponding 4'-spirocyclobutanols and these intermediates were found to be excellent substrates for as tereoselective Vorbrüggen glycosylation. This reproducible, high-yielding synthesis route enables access to multigram quantities of an ovel class of 4'-spirocyclobutyl adenosine analogues in eight steps from commercially availables ugar building blocks. Ap roof of concept was delivered that 4'-spirocyclic buildingb locks can be transformed into potent inhibitors for methyltransferase PRMT5.
